PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Tuesday, July 23, 2013

GSK's China crisis: questions for Witty that need answers

Posted on 9:14 PM by Unknown


The GlaxoSmithKline building in west London
The GlaxoSmithKline building in west London. Photograph: Luke Macgregor/Reuters

Sir Andrew Witty, chief executive of GlaxoSmithKline, will on Wednesday speak publicly for the first time about the cash and sexual bribery scandal that has led to the arrest of four of the company's senior Chinese executives.

Britain's biggest drug company has admitted some of its executives have broken the law, but has failed to explain who did it, what they did, when they did it or how long the company has known about it.

Here are eight questions that Witty – who was paid £3.9m last year– should answer when he speaks to the media on a conference call on Wednesday.

What have GSK staff actually done?

The Chinese authorities have accused GSK of acting like a criminal "godfather", using a network of 700 middlemen and travel agencies to bribe doctors with £320m cash and sexual favours in return for prescribing GSK drugs.

Gao Feng, head of China's fraud unit, said: "In order to win the favour of GSK, some travel agencies don't just offer money to their [clients], but also sexual bribes."

GSK has admitted only that "certain senior executives who know our systems well appear to have acted outside of our processes and controls which breaches Chinese law". But it has refused to explain exactly what they did or how the alleged bribery worked, despite one of the detained executives admitting to the charges on Chinese state television.

How long have GSK China executives been allegedly breaking the law?

Gao said the police have evidence that bribery has been a "core part" of GSK China's business model since 2007.

GSK said it was "deeply concerned and disappointed" by the allegations, but it has refused to say how long the alleged bribery has been going on.

How much did GSK pay out in bribes? Did this inflate the price of GSK's drugs to patients?

Gao claims GSK spent 3bn yuan (£320m) on bribes. GSK has refused to comment.

One of the arrested executives, Liang Hong, told Chinese state TV that it raised prices Chinese consumers pay for GSK's drugs by up to 30%.

Abbas Hussain, the company's head of emerging markets who was dispatched to Shanghai to oversee the crisis, has promised it will cut the price of its drugs in China.

When did GSK first become aware of these allegations and why did Witty not address accusations of wrongdoing in China earlier?

The Chinese authorities announced the charges and arrested the four GSK executives on 15 July – this was just a week after the company said a four-month internal investigation found "no evidence of corruption or bribery in our China business".

That internal investigation was prompted by a whistleblower who wrote to GSK's board this year alleging that Chinese sales staff had been engaged in the "widespread bribery of doctors to prescribe drugs".

GSK's operations in China have long been plagued by allegations of bribery and corruption. Last year, GSK sacked 56 employees in China for violating its rules, out of a worldwide total of 312 dismissals.

The New York Times claims it has seen an internal audit showing GSK was warned about serious problems in its Chinese research and development facilities as early as November 2011. The report includes a claim that GSK failed to release the results of a drug trial on mice when it was already testing the drug on humans.

How far up the corporate food chain did the corruption reach?

GSK has refused to say how many of its executives appear to have breached Chinese laws, or name any individuals it suspects. Sources close to the company suggest the allegations are restricted to the four Chinese executives detained by the police.

However, the Chinese police are preventing GSK China's British finance director Steve Nechelput from leaving the country, and want Mark Reilly, the British boss of GSK China, to return to Shanghai.

GSK has refused to comment on whether Nechelput or Reilly were involved or aware of the bribery allegations. The company has also refused to say if or when Reilly will return to China.

What will Witty do to clean up GSK's Chinese operations?

Hussain said GSK is taking the charges "extremely seriously" and will take "all necessary actions to … root out corruption wherever it exists", but the company has not so far given any details of specific measures it will take.

What information has GSK passed to the Serious Fraud Office?

GSK said it is regularly briefing the SFO, but has not said what information it has passed on.

Can Witty assure shareholders that staff in other countries are not bribing doctors?

Last year GSK paid a $3bn (£1.9bn) fine in the US to settle claims that it tricked and bribed doctors into prescribing dangerous antidepressants to children. After the settlement Witty vowed that a company-wide overhaul would prevent a repeat of the scandal.

Follow the Guardian's live blog of Witty's conference call with the media from noon on Wednesday at www.guardian.co.uk/business

http://www.guardian.co.uk/business/2013/jul/24/gsk-china-crisis-questions?

Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ▼  July (104)
      • Still a fantastic read
      • GlaxoChinaGate contd. - Nothing uniquely Chinese a...
      • Hope for the future
      • Slumdog clinical trials contd. - BMJ editorial: In...
      • Let the sunshine in
      • Hongbao - the red envelope
      • Sharing data from clinical trials: where we are an...
      • Pfizer Pleads Guilty, Pays $491 Million Over Rapam...
      • Caveat lector!
      • Now this is worrying
      • FDA toughens malaria drug labeling because sometim...
      • An addiction that is hard to break
      • GlaxoChinaGate contd. The case of Zhao Hongyan, th...
      • Perrigo buys Irish drug maker Elan in $8.6bn deal
      • 1boringoldman makes the case for data transparency
      • GSK investigation reveals something rotten - China...
      • The Glaxo-China Bribery Scandal: A New Policeman W...
      • UK pharma shows signs of dangerous addiction
      • Paul Krugman: China’s economy has hit its Great Wall
      • Class-action suit over Pfizer Canada's anti-smokin...
      • GlaxoChinaGate contd. - Reilly to return to China!
      • China state media says 18 more detained in GSK probe
      • Bergstroem's mobilising memo
      • GlaxoChinaGate contd.- The World of Suzie Wang
      • GlaxoChinaGate contd. - is this the payoff?
      • Big Pharma’s data sharing principles “weak and fil...
      • GlaxoChinaGate contd. - the Chinese police reveal ...
      • Banks and Big Pharmas hire private eyes who break ...
      • Pharma industry downplays lobbyism with patient gr...
      • Meanwhile, in other GSK news...
      • GlaxoChinaGate contd. Witty may not be forthcoming...
      • The World According to Monsanto
      • Patient groups commit to transparency after leaked...
      • GSK's China crisis: questions for Witty that need ...
      • More Astra staff held in China as GSK crisis deepens
      • Antimalarial Drug Linked to Sgt. Robert Bales Mass...
      • Drug Research in China Falls Under a Cloud
      • How to lower Big Pharma's drug prices the Chinese way
      • It's a strange old world
      • A message from AllTrials.net
      • GSK's China Crisis spreads
      • Files Suggest a Graft Case in China May Expand - NYT
      • AllTrials contd. Which patient groups are in Big P...
      • Healthcare in China: GSK claims prompt crackdown o...
      • More on Peter Humphrey, MD of ChinaWhys
      • GSK boss to address China scandal at quarterly res...
      • Killing the chicken to scare the monkey
      • GlaxoSmithKline briefs Serious Fraud Office over C...
      • Comment: China crisis growing for troubled Glaxo
      • China - getting in is easier than getting out!
      • GlaxoSmithKline's China crisis: why it changes the...
      • GlaxoSmithKline rushes executives to China to hand...
      • GSK chief Andrew Witty set to admit China 'scam’
      • Can Merck Finally Get Past the Vioxx Scandal?
      • NHS could save £84m using cheaper drug to prevent ...
      • Worth every penny
      • China - Now UCB get a visit
      • Johnson and Johnson Settles Suit Alleging Manageme...
      • GSK China's General Manager Mark Reilly Presents O...
      • Pharma Companies Must End Secret Gifts To Doctors ...
      • Eli Lilly to Freeze Employee Base Pay Ahead of Gen...
      • Latest MTRAC reviews
      • China bars Glaxo finance director from leaving cou...
      • GSK's Andrew Witty's new role in China
      • Four Drugmakers Face China Probes as Glaxo Woes Widen
      • A fish starts to rot from the head. After GSK, who...
      • Sexual Favors Spur Glaxo’s $1.5 Billion China Sale...
      • First GSK denied......
      • GSK China - Watch the confession
      • Anyone know where GSK's Mark Reilly is?
      • AZ - Exit the gas man
      • Do Clinical Trials Work? - NYT
      • David Healy vs AbbVie - A good medicine is a chemi...
      • UK NHS hit for millions by overcharging ‘scam’ - ...
      • Chinese clinical trials probed
      • Did Big Pharma team up to kill British Columbia's ...
      • Japan vows action over claims of fabricated drug data
      • Stopping Big Pharma From Using New .pharmacy Domai...
      • Our medical schools must not become shills for big...
      • GSK vs PSB
      • China security ministry says GSK executives confes...
      • Merck 'Evergreens' Off-Patent Lipitor By Creating ...
      • Wolfe Attack!
      • Drug Rep$
      • Are Clinical Trial Data Shared Sufficiently Today?
      • Stop blanket animal antibiotics now - before it's ...
      • Castellani vs Goldacre
      • Recent €23 Million Biotech IPO Relied Heavily On Q...
      • Australia targets Nurofen
      • New bribery allegations hit GlaxoSmithKline in China:
      • GSK's Dierdre P. Connelly makes a promise
      • Gouging contd. - How to make a $300 drug cost $30,...
      • "It may have been Roaccutane"
      • Ghost- and Guest-Authored Pharmaceutical Industry-...
      • Drs. Oz & Roizen's Tip of the Day: What's up with ...
      • Tchotchke War Looms
      • Ten tips when writing about clinical trials by Rut...
      • Pfizer and Merck
      • An interesting case
      • Pharma "a prime target" of govt health cuts in 201...
      • Sanofi to cut 207 R&D jobs in latest French reshuffle
      • Clot Wars contd.
      • GlaxoSmithKline Probe in China Follows Drug Safety...
      • Merck's Mess
    • ►  June (81)
    • ►  May (5)
Powered by Blogger.